Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic
31. Juli 2018 16:30 ET
|
Emergent BioSolutions
ZIKV-IG granted Fast Track designation by the U.S. Food and Drug Administration GAITHERSBURG, Md., July 31, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the...